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ABSTRACT 
The Triggering Receptor Expressed on Myeloid cells 1 (TREM-1) is a cell surface 
receptor of the immunoglobulin superfamily, involved in the propagation of the 
inflammatory response to bacterial challenge.  Soluble (s)TREM-1 is released from 
the cell surface during the course of infection, and is a useful inflammatory biomarker 
in the early diagnosis of systemic sepsis. The hypothesis of this study is that oral and 
systemic levels of sTREM-1 are elevated in periodontitis. Therefore, the aim was to 
investigate by ELISA the sTREM-1 concentrations in saliva and serum of non- 
periodontitis subjects (control) and patients with chronic or generalized aggressive 
periodontitis. In saliva, sTREM-1 concentrations were higher in chronic and 
aggressive periodontitis than the control group, by 3.3-fold and 5.6-fold, respectively. 
In serum, these differences were 1.7-fold and 2-fold, respectively. However, there 
were no significant differences between the two forms of periodontitis, neither in 
saliva nor in serum. Salivary and serum sTREM-1 levels positively correlated with 
full mouth clinical periodontal parameters. In conclusion, the increased oral and 
systemic levels of sTREM-1 in periodontitis denote a value for this molecule as a 
biomarker for the disease, and may also have implications in the association between 
periodontal infections and systemic inflammatory response. 
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INTRODUCTION 
The Triggering Receptor Expressed on Myeloid cells 1 (TREM-1) is a cell surface 
receptor of the immunoglobulin superfamily, involved in the innate inflammatory 
response to bacterial and fungal infections (Bleharski et al., 2003). Early studies have 
demonstrated the role of TREM-1 the development of septic shock (Begum et al., 
2004; Bouchon et al., 2001). It was further demonstrated that the systemic production 
of TREM-1 is enhanced in infections of the respiratory track, gut or the amniotic fluid 
(Begum et al., 2004; Buckland et al., 2011). TREM-1 is produced primarily by 
monocytes (Arts et al., 2011; Cavaillon, 2009) and regulates immune cell functions in 
a manner that leads to the enhancement of the inflammatory response (Colonna and 
Facchetti, 2003; Ford and McVicar, 2009). The engagement of TREM-1 in in vivo 
and in vitro models by agonist monoclonal antibodies further stimulates the 
production of pro-inflammatory cytokines (Bleharski et al., 2003; Bostanci et al., 
2011; Bouchon et al., 2001; Radsak et al., 2004). A synergism exists between the 
activation of TREM-1 and toll-like receptors or Nod-like receptors, resulting in 
amplification of pro-inflammatory cytokines, including tumor necrosis factor (TNF)-
α, interleukin (IL)-1β, and inhibition of anti-inflammatory cytokines such as IL-10 
(Bleharski et al., 2003). Hence, the role of TREM-1 in innate immunity appears to be 
the regulation of the magnitude of the inflammatory response to bacterial challenge. 
Of relevance to periodontal disease is the finding that Porphyromonas gingivalis 
induces TREM-1 production in monocytes, characterised by a shift from the cell 
bound to its soluble form, along with the propagation of pro-inflammatory cytokine 
production (Bostanci et al., 2011; Liang et al., 2009). This effect can be diminished by 
the administration of doxycycline in the experimental system (Bostanci and 
Belibasakis, 2012). 
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As TREM-1 is released during the course of infection in the form of soluble 
(s)TREM-1, it can serve as a particularly useful marker of systemic inflammation. 
This has been well demonstrated in systemic sepsis (Gibot et al., 2004a; Gibot et al., 
2004b; Su et al., 2012), arthritis (Collins et al., 2009; Murakami et al., 2007), 
pulmonary infections (Ruiz-Gonzalez et al., 2011), pancreatitis (Yasuda et al., 2008) 
and inflammatory bowel disease (Park et al., 2009). sTREM-1 is a biomarker that can 
easily be measured in biological fluids (Skogstrand et al., 2005). The presence of 
sTREM-1 in serum could be attributed to circulating leukocytes during the course of 
systemic infection, or could account for locally produced sTREM-1 in focal 
infections, which eventually enters the blood stream (Bleharski et al., 2003). 
Even though the systemic involvement of sTREM-1 has been demonstrated in 
a number of infections, little is known about its association with periodontal disease. 
Thus the hypothesis of this study is that oral and systemic TREM-1 levels are elevated 
in periodontitis, and could constitute a systemic biomarker for the disease. Therefore, 
the aim of the study was to investigate the salivary and serum sTREM-1 levels, in 
subjects without periodontitis and patients with chronic or aggressive periodontitis.  
 
MATERIALS AND METHODS 
Study population and clinical examination 
A total of 63 subjects were included in this study, recruited from the Department of 
Periodontology, School of Dentistry, Ege University, İzmir, Turkey, from November 
2011 until March 2012. The use of human subjects satisfied the requirements of Ege 
University Institutional Review Board (ethics approval number: 11-12.1/11) and was 
conducted in accordance with the guidelines of the World Medical Association 
Declaration of Helsinki. It is confirmed that this cross-sectional study conforms to 
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STROBE guidelines for observational studies. Complete medical and dental histories 
were taken from all subjects. Systemic exclusion criteria were presence of 
cardiovascular and respiratory diseases, diabetes mellitus, HIV infection, systemic 
inflammatory conditions or non-plaque induced oral inflammatory conditions, 
immunosuppressive chemotherapy and current pregnancy or lactation. None of the 
patients had taken medication such as antibiotics or anti-inflammatory drugs that 
could affect their periodontal status for at least 6 months before the study. Patients 
eligible for the study returned to the clinic for clinical measurement screening, 1 week 
after pre-screening. Smoking status was also recorded, and participants smoking > 5 
cigarettes per day were registered as smokers. Prior to enrolment in the study, written 
and informed consent was obtained from each subject. Patient selection was based on 
clinical and radiographic criteria proposed by the 1999 International World Workshop 
for a Classification of Periodontal Disease and Conditions (Armitage, 1999). The 
clinical measures and patient demographics are described in the Appendix. 
 
Collection and processing of saliva and serum 
All clinical samples (saliva and serum) were collected in the morning between 8 a.m. 
and 11 a.m. Subjects were asked to avoid oral hygiene measures (i.e., flossing, 
brushing, and mouth rinses), eating, drinking for 2 h before collection. For saliva 
collection, the subjects asked to rinse their mouth with tap water, following which 
they expectorated whole saliva into sterile 50 ml tubes for 5 min. All saliva samples 
were placed on ice, supplemented with EDTA-free Protease Inhibitor Cocktail (Roche 
Applied Science, Switzerland) prior to centrifuging at 10000 x g for 15 min at 4°C 
(Navazesh, 1993). Finally, the resulting supernatants were then immediately aliquoted 
and frozen at - 80°C. For serum samples, 5 ml of venous blood were taken into 
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vacutainers (BD Diagnostics) by a standard venipuncture method. Once collected, the 
samples were left at room temperature to allow for blood clotting, and then 
centrifuged to remove the fibrin clot and cellular elements for 15 min at 1500 x g at 
4°C. All serum samples were placed on ice, supplemented with EDTA-free Protease 
Inhibitor Cocktail (Roche Applied Science, Switzerland). Finally, they were 
immediately aliquoted and frozen at – 80 °C. Further analysis of the saliva and serum 
samples by ELISA is described in the Appendix. 
 
Statistical analysis 
Statistical analysis was performed using non-parametric methods. Comparisons 
between all groups were performed using the Kruskal–Wallis test. When significant 
differences were observed (p<0.008), then two-group comparisons were assessed with 
Mann–Whitney U-tests with Bonferroni correction, and p<0.05 was considered to be 
statistically significant. Correlations between sTREM-1 levels and clinical parameters 
were analyzed by Spearman's rank test and p < 0.01 values were considered as 
significant. Statistical analyses were conducted using the statistical software SPSS v. 
19.0 (IBM, Somers, NY, USA). 
 
RESULTS 
Clinical findings 
The full mouth clinical findings are provided in Table 1. Mean probing pocket depth, 
clinical attachment loss, plaque index and bleeding on probing scores were 
significantly higher in the chronic and generalized aggressive periodontitis groups, 
than in the control group (p < 0.0001). No significant differences were detected in 
these clinical measurements between the two periodontitis groups. 
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Analysis of sTREM-1 levels in saliva 
Saliva samples were collected from 59 subjects (control: n = 18, chronic periodontitis: 
n = 20, generalized aggressive periodontitis: n = 21). The concentrations of sTREM-1 
in these samples were further analyzed by ELISA.  sTREM-1 was detected in all of 
the samples. The mean concentrations were 384.60 ± 115.81 pg/ml in the control 
group, 1272.38 ± 138.91 pg/ml in chronic periodontitis (3.3-fold higher than the 
control) and 2179.95 ± 306.14 pg/ml in generalized aggressive periodontitis (5.6-fold 
higher than the control) (Fig. 1A). The differences between the control group and 
either form of periodontitis were statistically significant, whereas the difference 
between the two forms of periodontitis was not. Since salivary flow rate may reflect 
differences in composition, the salivary sTREM-1 concentrations were also corrected 
for total protein content. It was found that total protein concentrations were 1.73 ± 
0.28 mg/ml, 2.03 ± 0.31 mg/ml and 2.49 ± 0.43 mg/ml, in the control group, chronic 
periodontitis and generalized aggressive periodontitis, respectively. Accordingly, the 
calibrated-to-protein salivary levels of sTREM-1 were 212.18 ± 32.23 pg/mg, 914.45 
± 170.99 pg/mg and 1127.16 ± 133.63 pg/mg, in the control group, chronic 
periodontitis (4.3-fold higher than control) and generalized aggressive periodontitis 
(5.3-fold higher than control), respectively (Fig. 1B). The differences between the 
control group and chronic or generalized aggressive periodontitis were statistically 
significant (p < 0.0001), whereas the difference between these two forms of 
periodontitis was not. Salivary sTREM-1 levels (both pg/ml and pg/mg protein) 
correlated positively (p < 0.01) with all full mouth clinical parameters measured 
(Table 2). There were no significant differences in salivary sTREM-1 concentrations 
or calibrated-to-protein amounts between smokers and non-smokers. There was also a 
positive correlation between IL-1β and sTREM-1 concentrations and calibrated-to-
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protein amounts in saliva (r = 0.587 and r = 0.565, respectively, p < 0.05). The 
analysis of IL-1β levels in saliva is provided in the Appendix.  
 
Analysis of sTREM-1 levels in serum 
Serum samples were available from 62 subjects (control: n = 20, chronic 
periodontitis: n = 22, generalized aggressive periodontitis: n = 20) and analyzed by 
ELISA for the concentrations of sTREM-1, which was detected in all samples. These 
concentrations were 306.49 ± 18.65 pg/ml in the control group, 536.89 ± 43.98 pg/ml 
in chronic periodontitis and 621.7 ± 54.35 pg/ml in generalized aggressive 
periodontitis (Fig. 2). These differences represent a 1.75-fold increase in chronic 
periodontitis and a 2-fold increase in generalized aggressive periodontitis, compared 
to the control group. The differences between the control group and either form of 
periodontitis were statistically significant (p < 0.0001), whereas there were no 
differences between the two forms of periodontitis. Serum TREM-1 levels also 
positively correlated (p < 0.01) with all full mouth clinical parameters (Table 2). 
There was no significant difference (p > 0.05) in sTREM-1 serum concentrations 
between smokers and non-smokers. 
 
Correlation analysis between saliva and serum sTREM-1 levels 
The potential correlation between sTREM-1 levels in saliva and serum was also 
investigated, in the 58 subjects with the available matched samples, a positive 
correlation between sTREM-1 concentrations in serum and saliva was revealed (r = 
0.48, p < 0.0001). 
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DISCUSSION 
The present study is the first to investigate the oral and systemic levels of sTREM-1 
in periodontal disease, by analysing its concentrations in serum and saliva, 
respectively. The results demonstrate that the levels of sTREM-1 in saliva and serum 
are significantly higher in patients with chronic and generalized aggressive 
periodontitis, compared to subjects without periodontitis. There are no differences 
between these two forms of periodontitis. Moreover, a positive correlation is revealed 
between clinical periodontal measurements and levels of sTREM-1. This indicates 
that the occurrence and severity of periodontitis matches with elevated oral and 
systemic sTREM-1 levels. Taken the involvement of this molecule in the propagation 
of the local and systemic inflammatory response, these findings could provide a 
further link between periodontitis and systemic inflammation (Hasturk et al., 2012).  
A number of systemic biomarkers have been studied to assess their relevance 
to periodontal health and disease. For instance, C-reactive protein (CRP), a systemic 
marker of the acute phase inflammatory response, has been measured in saliva and 
serum, and can differentiate periodontal health from periodontal disease, as its levels 
are elevated in disease (Christodoulides et al., 2005; D'Aiuto et al., 2004). When 
compared to CRP or procalcitonin, a marker that can differentiate between infectious 
and non-infectious inflammation, serum and urine sTREM-1 shows higher sensitivity 
and specificity for detecting systemic inflammation in early bacterial sepsis (Su et al., 
2012). In this respect, sTREM-1 could well serve as a biomarker representative of the 
inflammatory state of the infected periodontal tissues. The nature of periodontitis as a 
focal infection and its well documented association with systemic inflammation, 
provide a good rationale for studying sTREM-1 systemic responses in this disease. 
Indeed, the present data demonstrates a significant increase of salivary and serum 
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sTREM-1 in periodontitis compared to non-periodontitis, as well as a positive 
correlation with disease severity. Moreover, the data provides evidence of a positive 
correlation between sTREM-1 and IL-1β levels in saliva. This association is in line 
with in vitro findings that TREM-1 activation enhances IL-1β production (Bostanci et 
al., 2011), although the present approach can not directly reveal a cause-effect 
relationship between the two molecules in saliva. Saliva in particular is a favourable 
biological analyte for monitoring oral and systemic disease biomarkers, due to its 
non-invasive collection and natural presence in the totality of the oral cavity 
(Giannobile et al., 2009; Ramseier et al., 2009; Zhang et al., 2009). Hence, the 3-fold 
to 6-fold increase of sTREM-1 salivary levels in periodontitis can denote the 
magnitude of pathological regulation, opening the possibility for the use of sTREM-1 
as a quantitative biomarker for undiagnosed periodontal disease. At this point, one 
should take also under consideration that proteinases produced by oral bacteria, 
particularly the ones associated with periodontitis, could well degrade sTREM-1 
released in saliva. This would mean that the original production of sTREM-1 may be 
greater than what is eventually is detected in the salivary environment. 
It is likely that inflammatory biomarkers of oral disease would be considerably 
diluted in serum, compared to saliva. This is also reflected in the present study, 
whereby sTREM-1 concentrations in periodontitis were by 2-fold higher in saliva 
than in serum. As periodontal disease can be a mediator of systemic inflammation and 
a modifier of the effect of the association with systemic disease, such as diabetes 
mellitus (Lalla and Papapanou, 2011), sTREM-1 could provide a risk indicator for 
systemic inflammation. In the present study, the periodontitis patients were otherwise 
systemically healthy, with no other indication of an inflammatory or infectious 
process, and demonstrated almost 2-fold higher sTREM-1 serum levels, compared to 
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subjects without periodontitis. Hence, once could postulate that the occurrence of 
periodontitis alone increases by 2-fold the circulating levels of sTREM-1, and 
consequently any biological effect that this factor may have on the systemic level. 
Whether the increased presence of sTREM-1 in the serum of periodontitis patients 
results from bacteraemic challenge of circulating leukocytes by periodontal 
pathogens, or represents a “leakage” of locally produced sTREM-1 into the 
circulation remains unclear. Finally, it is worth noting that as salivary and serum 
sTREM-1 does not appear to be affected by smoking, unlike other inflammatory 
markers (i.e. CRP and several cytokines), it may prove to be a useful biomarker. 
Collectively, the present study shows an increase of oral and systemic levels 
of sTREM-1 in periodontitis. The two main limitations of the study have been its 
cross-sectional nature, which can only confer an association between sTREM-1 and 
periodontitis, but can not reveal a mechanistic insight or a predictive value for the 
disease, and the relatively small sample size. Whether sTREM-1 release constitutes a 
mechanism that contributes to the progression of the disease, or a protective 
inflammatory reaction to emerging bacterial infection, remains to be elucidated. 
Whichever the case, the increased presence of this molecule may stand as a biomarker 
of underlying periodontal disease. This can have diagnostic implications in the 
detection of untreated periodontitis, but could also denote an increase in the systemic 
inflammatory burden, in the presence of the disease. In either case, the physiological 
and/or pathological roles of sTREM-1 in periodontal inflammation need to be further 
enlightened in order to justify its potential value as an indicative or predictive oral 
biomarker of the disease, or as an indicator of the association between periodontal 
disease and systemic inflammation.  
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TABLES 
Table 1. Full mouth clinical periodontal measurements (mean ± standard deviations) 
of the three study groups. 
Clinical parameters Control  (n = 20) 
Chronic 
Periodontitis  
(n = 22) 
Generalized 
Aggressive 
Periodontitis  
(n = 21) 
Probing pocket depth (mm) 1.80 ± 0.26 4.95 ± 0.37 * 5.32 ± 0.77 * 
Clinical attachment loss (mm) 1.83 ± 0.28 5.56 ± 0.67 * 6.02 ± 1.07 * 
Plaque index 0.85 ± 0.39 2.35 ± 0.48 * 2.09 ± 0.44 * 
Bleeding on probing (%) 25 ± 15 74 ± 41 * 66 ± 21 * 
*p < 0.0001  
 
Table 2. Spearman’s rank correlation analysis between full mouth clinical periodontal 
parameters and TREM-1 levels saliva and serum. 
Clinical parameters Serum (pg/ml) Saliva (pg/ml) Saliva (pg/mg) 
Probing pocket depth r =  0.674 * r = 0.672 * r =  0.694 * 
Clinical attachment loss r = 0.725 * r = 0.640 * r = 0.725 * 
Plaque index r = 0.525 * r = 0.544 * r = 0.589 * 
Bleeding on probing r = 0.427 * r = 0.674 * r = 0.583 * 
* p < 0.01 
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FIGURE LEGENDS 
 
Figure 1. Distribution of TREM-1 levels in saliva from subjects without periodontitis 
(control) (n = 18), with chronic periodontitis (n = 20) and with generalized aggressive 
periodontitis (n = 21) subjects. The individual values represent salivary (A) 
concentrations (in pg/ml) or (B) amounts (in pg/mg of protein) of TREM-1 in each 
subject. The horizontal lines indicate median values. The asterisk represents 
significant difference compared to the control group (* p < 0.0001). The difference 
between the chronic periodontitis and generalized aggressive periodontitis groups was 
not significant. 
 
Figure 2. Distribution of TREM-1 levels in serum from subjects without periodontitis 
(the control group) (n = 20), chronic periodontitis (n = 22) and generalized aggressive 
periodontitis (n = 20) subjects. The individual values represent serum concentrations 
(in pg/ml) of TREM-1 in each subject. The horizontal lines indicate median values. 
The asterisk represents significant difference compared to the control group (* p < 
0.0001). The difference between the chronic and generalized aggressive periodontitis 
groups was not significant. 
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APPENDICES 
 
Materials and Methods 
 
Patient demographics and clinical measures 
The periodontal status of each patient was assessed by a single calibrated examiner 
having experience in clinical trials (O.V.O). Full mouth clinical periodontal 
examination included measurement of probing pocket depth, clinical attachment level 
at six sites around each tooth with a manual probe, full-mouth dichotomous presence 
of bleeding on probing and plaque index (Loe, 1967). The following values represent 
means ± standard deviation. The control group consisted of 6 females and 14 males 
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(from 21 to 64 years, mean age 36.0 ± 2.6 years) with varying levels of gingival 
inflammation as indicated by bleeding on probing scores, but no radiographic 
evidence of alveolar bone loss (i.e., distance between the cemento-enamel junction 
and bone crest ≤3 mm at >95% of the proximal tooth sites). This control group is 
collectively considered as the “non-periodontitis” group in the context of this study. 
The chronic periodontitis group included 13 females and 9 males (from 33 to 62 
years, mean age of 44.1 ± 7.7 years). They had at least 4 non-adjacent teeth with sites 
of clinical attachment loss ≥5 mm, which was commensurate with the amount of 
plaque accumulation, and probing pocket depth ≥6 mm. Full mouth bleeding on 
probing was more than 50%. The generalized aggressive periodontitis group consisted 
of 12 females and 9 males (from 23 to 42 years, mean age 34.2 ± 5.3 years). These 
patients demonstrated a generalized pattern of severe destruction and clinical 
attachment loss ≥5 mm and pocket depth ≥6 mm on eight or more teeth, at least three 
of these were other than central incisors or first molars. All subjects had at least 20 
teeth in their mouth. The extent and severity of bone support and/or osseous lesions 
were evaluated radiographically in each patient. The distribution of smokers was 4/20 
in the non-periodontitis group, 7/22 in the chronic periodontitis group, and 7/21 in the 
generalized aggressive periodontitis group. 
 
Analysis of TREM-1 and IL-1β levels by ELISA 
The levels of sTREM-1 in saliva or serum, and the levels of IL-1β in saliva were 
measured by a commercially available specific enzyme-linked immunosorbent assay 
(ELISA) kit, according to the manufacturer’s instructions (R&D Systems, Abingdon, 
UK). The absorbance at 450 nm was measured using a microplate reader (Epoch, 
BioTek, Luzern, Switzerland), with a wavelength correction set at 570 nm to subtract 
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background. A standard curve was generated using a four-parameter logistic curve fit 
for each set of samples assayed. All samples were run in duplicate wells. The 
sensitivity of the sTREM-1 ELISA assay was 46 pg/ml, whereas that of the IL-1β 
ELISA assay was 1.7 pg/ml. The concentrations of sTREM-1 in saliva were also 
expressed as pg/mg of protein, after normalization against total protein levels. The 
total protein content of saliva was quantified with the BCA Protein Assay Kit 
(Thermo Scientific Pierce, Switzerland) as mg/ml. 
 
Results 
Analysis of IL-1β levels in saliva 
IL-1β concentrations were significantly higher in chronic periodontitis (163.62 ± 
28.59 pg/ml, p < 0.05) and generalized aggressive periodontitis (334.34 ± 91.73 
pg/ml, p < 0.0001), compared to the control group (97.77 ± 14.28 pg/ml). The 
difference between the two forms of periodontitis was also significant (p = 0.03). 
When the calibrated-to-protein IL-1β levels were considered, these were significantly 
higher in chronic periodontitis (107.28 ± 17.63 pg/mg, p = 0.05) and generalized 
aggressive periodontitis (151.61 ± 31.24 pg/mg, p = 0.02), compared to the control 
group (64.39 ± 10.18 pg/mg).  
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